Turco, Fabio http://orcid.org/0000-0003-3111-7888
Gillessen, Silke
Treglia, Giorgio http://orcid.org/0000-0001-9808-780X
Fizazi, Karim
Smith, Matthew R.
Tombal, Bertrand http://orcid.org/0000-0002-0093-8408
Cathomas, Richard
Buttigliero, Consuelo
Di Maio, Massimo http://orcid.org/0000-0001-8906-3785
Tucci, Marcello http://orcid.org/0000-0002-4977-116X
Vogl, Ursula M.
Article History
Received: 1 October 2023
Revised: 21 November 2023
Accepted: 30 November 2023
First Online: 14 December 2023
Competing interests
: FT: travel grant: Bayer. SG: (last 3 years) personal honoraria advisory boards from Amgen, MSD; invited speaker ESMO, Swiss group for Clinical Cancer Research (SAKK), German-speaking European School of Oncology (DESO), Swiss Academy of Multidisciplinary oncology (SAMO); travel grant from AstraZeneca, Bayer. Institutional honoraria advisory boards or in Independent Data Monitoring-/Steering Committees from AAA International, Amgen, AstraZeneca, Astellas Pharma, Bayer, Boehringer Ingelheim, Bristol-Myers Squibb, DAIICHI Sankyo, Innomedia, Ipsen, Modra Pharmaceuticals, MSD, Myriad Genetic, Novartis, Orion, Pfizer, Roche, Telixpharma; invited speaker SAKK, ASCO GU, ESMO, PeerVoice, Silvio Grasso Consulting, WebMD-Medscape. Patent for a research method for biomarker WO2009138392. GT: no conflicts of interest. KF: participation in advisory boards and talks for Amgen, Astellas, AstraZeneca, Bayer, Clovis, Daiichi Sankyo, Janssen, MSD, Novartis/AAA, Pfizer, Sanofi Honoraria go to Gustave Roussy, my institution. Participation to advisory boards with personal honorarium for Arvinas, CureVac, Macrogenics and Orion. MRS: consultant to Ambrx, Astellas, Bayer, Pfizer, Janssen, Lilly. BT: consultant and advisor for Amgen, Astellas, AstraZeneca, Bayer, Ferring, Janssen, Myovant, Novartis, Pfizer. RC: consultation or participation at advisory boards (institutional): AstraZeneca, Astellas, Bayer, Janssen, Roche, Pfizer, Novartis, MSD, BMS, Ipsen, Debiopharm, Accord, Merck; honoraria (institutional): Ipsen, Astellas, Janssen, Merck Travel support (institutional): Ipsen. CB: no conflicts of interest. MDM: honoraria from AstraZeneca, Boehringer Ingelheim, Janssen, Merck Sharp & Dohme (MSD), Novartis, Pfizer, Roche, GlaxoSmithKline, Amgen, Merck, Takeda for consultancy or participation to advisory boards; institutional research funding from Tesaro/GlaxoSmithKline; institutional funding for work in clinical trials/contracted research from Beigene, Exelixis, MSD, Pfizer and Roche. MT: no conflicts of interest. UV: grant: Fond’Action; Institutional: Pfizer, Astellas, Janssen, Sanofi, Merck, MSD, BMS, Ipsen, Health Book, Novartis, Bayer Private: Health Book, SAMO, Inselspital Bern, Kantonsspital Chur, Kantonsspital Baden, Ipsen; Travel Grant: AstraZeneca, Janssen.